AstraZeneca introduced SGLT-2 inhibitor based diabetes treatment 'Dapaglifozin' in the market
On Mar 19, AstraZeneca prepared the place in Westin Chosun Seoul, to introduce SGLT-2 inhibitor based diabetes treatment 'Dapaglifozin' which got the nation's first approval from Ministry of Food and Drug Safety.
Dapagliflozin is a SGLT-2 inhibitor. It blocks SGLT-2 receptors in urine which are ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
